Oncothyreon enrolls first patient in Phase II trial of PX-866 for CRPC

Oncothyreon, Inc. has announced initiation of a Phase II clinical trial of the company’s investigational agent PX-866 in the treatment of men with chemotherapy-naïve, recurrent or metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …